1914078-41-3 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl N-[4-(4-amino-1-2-[4-(dimethylamino)piperidin-1-yl]ethyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]carbamate is used as a pharmaceutical compound for its potent antiproliferative effects on various cancer cell lines, such as MCF7 and MDA-MB-231 cells. It inhibits the phosphorylation of SRC and FAK at low nanomolar levels, with complete inhibition observed at 100 nM, making it a promising candidate for cancer treatment.
Used in Drug Development:
In the field of drug development, tert-butyl N-[4-(4-amino-1-2-[4-(dimethylamino)piperidin-1-yl]ethyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]carbamate can be utilized as a lead compound for the development of novel therapeutic agents targeting cancer cells. Its ability to inhibit key signaling pathways involved in cell proliferation and survival makes it a valuable asset in the search for effective cancer treatments.
Used in Chemical Research:
Tert-butyl N-[4-(4-amino-1-2-[4-(dimethylamino)piperidin-1-yl]ethyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl]carbamate can also be employed in chemical research as a starting material or intermediate for the synthesis of other complex organic molecules with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 1914078-41-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,9,1,4,0,7 and 8 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1914078-41:
(9*1)+(8*9)+(7*1)+(6*4)+(5*0)+(4*7)+(3*8)+(2*4)+(1*1)=173
173 % 10 = 3
So 1914078-41-3 is a valid CAS Registry Number.
1914078-41-3Relevant academic research and scientific papers
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase
Fraser, Craig,Dawson, John C.,Dowling, Reece,Houston, Douglas R.,Weiss, Jason T.,Munro, Alison F.,Muir, Morwenna,Harrington, Lea,Webster, Scott P.,Frame, Margaret C.,Brunton, Valerie G.,Patton, E. Elizabeth,Carragher, Neil O.,Unciti-Broceta, Asier
supporting information, p. 4697 - 4710 (2016/06/13)
Novel pyrazolopyrimidines displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner. Compounds were derived from the promiscuous kinase inhibitor PP1 to search for analogs that could potentially target a broad spectrum of kinases involved in cancer. Phenotypic screening against MCF7 mammary adenocarcinoma cells generated target-agnostic structure-activity relationships that biased subsequent designs toward breast cancer treatment rather than to a particular target. This strategy led to the discovery of two potent antiproliferative leads with phenotypically distinct anticancer mode of actions. Kinase profiling and further optimization resulted in eCF506, the first small molecule with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concentration to inhibit ABL. eCF506 exhibits excellent water solubility, an optimal DMPK profile and oral bioavailability, halts SRC-associated neuromast migration in zebrafish embryos without inducing life-threatening heart defects, and inhibits SRC phosphorylation in tumor xenografts in mice.
